Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Mar;91(3):415–420. doi: 10.1111/j.1365-2249.1993.tb05918.x

Serum markers of T cell activation in relapses of Wegener's granulomatosis.

C A Stegeman 1, J W Tervaert 1, M G Huitema 1, C G Kallenberg 1
PMCID: PMC1554716  PMID: 8443965

Abstract

Levels of soluble IL-2 receptor (sIL-2R), soluble CD4 (sCD4) and CD8 (sCD8) were measured by sandwich ELISA as markers for T cell activation in serial serum samples from 16 patients showing 18 histologically proven relapses of Wegener's granulomatosis (WG). Levels of sIL-2R increased from 1065 U/ml (median, range 373-2345 U/ml) 6 months before the relapse to 1684 U/ml (median, range 486-3404 U/ml) at the moment of relapse for the whole group (P = 0.10). The eight major relapses showed a profound rise in sIL-2R levels, from 1008 U/ml (median, range 686-1553 U/ml) 6 months before the relapse, to 1994 U/ml (median, range 1469-3404 U/ml) at the moment of relapse (P < 0.01). The levels of sIL-2R at the moment of relapse were significantly higher at the eight major relapses than at the time of the 10 minor relapses (P < 0.05). Minor relapses were not accompanied by a significant rise in sIL-2R levels. Titres of antineutrophil cytoplasmic antibodies (ANCA) rose by two or more titresteps or from negative to positive in 15/18 patients during the 6 months period before the relapse. In all seven cases with both a rise of the ANCA titre and an at least 25% increase in sIL-2R levels, the rise in ANCA preceded the rise in sIL-2R by at least 1 month. The level of sIL-2R at the moment of relapse correlated with the level of C-reactive protein (r = 0.488, P < 0.05) and with the disease activity score (r = 0.824, P < 0.002). There were no significant changes in levels of sCD4 or sCD8, although the levels of sCD4 tended to be higher at the time of major relapses. We conclude that major relapses of Wegener's granulomatosis are accompanied by systemic T cell activation. T cell activation, however, does not appear to precede the rise in ANCA titre.

Full text

PDF
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brynskov J., Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut. 1990 Jul;31(7):795–799. doi: 10.1136/gut.31.7.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Campen D. H., Horwitz D. A., Quismorio F. P., Jr, Ehresmann G. R., Martin W. J. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988 Nov;31(11):1358–1364. doi: 10.1002/art.1780311103. [DOI] [PubMed] [Google Scholar]
  3. Clements P. J., Peter J. B., Agopian M. S., Telian N. S., Furst D. E. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil. J Rheumatol. 1990 Jul;17(7):908–910. [PubMed] [Google Scholar]
  4. Degiannis D., Seibold J. R., Czarnecki M., Raskova J., Raska K., Jr Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum. 1990 Mar;33(3):375–380. doi: 10.1002/art.1780330310. [DOI] [PubMed] [Google Scholar]
  5. Donati D., Degiannis D., Homer L., Gastaldi L., Raskova J., Raska K., Jr Immune deficiency in uremia: interleukin-2 production and responsiveness and interleukin-2 receptor expression and release. Nephron. 1991;58(3):268–275. doi: 10.1159/000186435. [DOI] [PubMed] [Google Scholar]
  6. Falk R. J., Jennette J. C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988 Jun 23;318(25):1651–1657. doi: 10.1056/NEJM198806233182504. [DOI] [PubMed] [Google Scholar]
  7. Fauci A. S., Haynes B. F., Katz P., Wolff S. M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76–85. doi: 10.7326/0003-4819-98-1-76. [DOI] [PubMed] [Google Scholar]
  8. Fauci A. S., Haynes B., Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 1978 Nov;89(5 Pt 1):660–676. doi: 10.7326/0003-4819-89-5-660. [DOI] [PubMed] [Google Scholar]
  9. Gephardt G. N., Ahmad M., Tubbs R. R. Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med. 1983 Apr;74(4):700–704. doi: 10.1016/0002-9343(83)91030-6. [DOI] [PubMed] [Google Scholar]
  10. Grau G. E., Roux-Lombard P., Gysler C., Lambert C., Lambert P. H., Dayer J. M., Guillevin L. Serum cytokine changes in systemic vasculitis. Immunology. 1989 Oct;68(2):196–198. [PMC free article] [PubMed] [Google Scholar]
  11. Hamzaoui K., Ayed K. Soluble interleukin 2 receptors in patients with Behçet's disease. J Rheumatol. 1989 Jun;16(6):852–853. [PubMed] [Google Scholar]
  12. Hind C. R., Winearls C. G., Lockwood C. M., Rees A. J., Pepys M. B. Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol. 1984 Jun;21(6):341–345. [PubMed] [Google Scholar]
  13. Holter W., Goldman C. K., Casabo L., Nelson D. L., Greene W. C., Waldmann T. A. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol. 1987 May 1;138(9):2917–2922. [PubMed] [Google Scholar]
  14. Kahaleh M. B. Soluble immunologic products in scleroderma sera. Clin Immunol Immunopathol. 1991 Jan;58(1):139–144. doi: 10.1016/0090-1229(91)90155-4. [DOI] [PubMed] [Google Scholar]
  15. Kallenberg C. G., Tervaert J. W., Stegeman C. A. Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies. APMIS Suppl. 1990;19:37–39. doi: 10.1111/j.1600-0463.1990.tb05725.x. [DOI] [PubMed] [Google Scholar]
  16. Kallenberg C. G., Tervaert J. W., van der Woude F. J., Goldschmeding R., von dem Borne A. E., Weening J. J. Autoimmunity to lysosomal enzymes: new clues to vasculitis and glomerulonephritis? Immunol Today. 1991 Feb;12(2):61–64. doi: 10.1016/0167-5699(91)90159-q. [DOI] [PubMed] [Google Scholar]
  17. Keicho N., Kitamura K., Takaku F., Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest. 1990 Nov;98(5):1125–1129. doi: 10.1378/chest.98.5.1125. [DOI] [PubMed] [Google Scholar]
  18. Keystone E. C., Snow K. M., Bombardier C., Chang C. H., Nelson D. L., Rubin L. A. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum. 1988 Jul;31(7):844–849. doi: 10.1002/art.1780310704. [DOI] [PubMed] [Google Scholar]
  19. Manoussakis M. N., Papadopoulos G. K., Drosos A. A., Moutsopoulos H. M. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol. 1989 Mar;50(3):321–332. doi: 10.1016/0090-1229(89)90140-2. [DOI] [PubMed] [Google Scholar]
  20. Nelson D. L., Rubin L. A., Kurman C. C., Fritz M. E., Boutin B. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol. 1986 Mar;6(2):114–120. doi: 10.1007/BF00918743. [DOI] [PubMed] [Google Scholar]
  21. Nölle B., Specks U., Lüdemann J., Rohrbach M. S., DeRemee R. A., Gross W. L. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. 1989 Jul 1;111(1):28–40. doi: 10.7326/0003-4819-111-1-28. [DOI] [PubMed] [Google Scholar]
  22. Rasmussen N., Petersen J., Ralfkiaer E., Avnstøm S., Wiik A. Spontaneous and induced immunoglobulin synthesis and anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis: relation to leukocyte subpopulations in blood and active lesions. Rheumatol Int. 1988;8(4):153–158. doi: 10.1007/BF00270453. [DOI] [PubMed] [Google Scholar]
  23. Reddy M. M., Lange M., Grieco M. H. Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected populations. J Clin Microbiol. 1989 Feb;27(2):257–260. doi: 10.1128/jcm.27.2.257-260.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  25. Rubin L. A., Snow K. M., Kurman C. C., Nelson D. L., Keystone E. C. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol. 1990 May;17(5):597–602. [PubMed] [Google Scholar]
  26. Sawada S., Sugai S., Iijima S., Takei M., Paredes E., Hayama T., Nishinarita S., Hosokawa Y., Horie T., Obara T. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome. Am J Med. 1992 Feb;92(2):134–140. doi: 10.1016/0002-9343(92)90103-i. [DOI] [PubMed] [Google Scholar]
  27. Stolc V., Krause J. R. Interleukin-2 receptor levels are increased in blood of heart transplant patients during infections. Diagn Clin Immunol. 1987;5(4):171–174. [PubMed] [Google Scholar]
  28. Symons J. A., McCulloch J. F., Wood N. C., Duff G. W. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol. 1991 Jul;60(1):72–82. doi: 10.1016/0090-1229(91)90113-o. [DOI] [PubMed] [Google Scholar]
  29. Symons J. A., Wood N. C., di Giovine F. S., Duff G. W. Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol. 1990 Jun;80(3):354–359. doi: 10.1111/j.1365-2249.1990.tb03292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tervaert J. W., Goldschmeding R., Elema J. D., Limburg P. C., van der Giessen M., Huitema M. G., Koolen M. I., Hené R. J., The T. H., van der Hem G. K. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum. 1990 Aug;33(8):1264–1272. doi: 10.1002/art.1780330829. [DOI] [PubMed] [Google Scholar]
  31. Tervaert J. W., Huitema M. G., Hené R. J., Sluiter W. J., The T. H., van der Hem G. K., Kallenberg C. G. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 1990 Sep 22;336(8717):709–711. doi: 10.1016/0140-6736(90)92205-v. [DOI] [PubMed] [Google Scholar]
  32. Tervaert J. W., Limburg P. C., Elema J. D., Huitema M. G., Horst G., The T. H., Kallenberg C. G. Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med. 1991 Jul;91(1):59–66. doi: 10.1016/0002-9343(91)90074-8. [DOI] [PubMed] [Google Scholar]
  33. Tervaert J. W., van der Woude F. J., Fauci A. S., Ambrus J. L., Velosa J., Keane W. F., Meijer S., van der Giessen M., van der Hem G. K., The T. H. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med. 1989 Nov;149(11):2461–2465. doi: 10.1001/archinte.149.11.2461. [DOI] [PubMed] [Google Scholar]
  34. Wolf R. E., Brelsford W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 Jun;31(6):729–735. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  35. Wong K. L., Wong R. P. Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection. Ann Rheum Dis. 1991 Oct;50(10):706–709. doi: 10.1136/ard.50.10.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. van der Woude F. J., van Es L. A., Daha M. R. The role of the c-ANCA antigen in the pathogenesis of Wegener's granulomatosis. A hypothesis based on both humoral and cellular mechanisms. Neth J Med. 1990 Apr;36(3-4):169–171. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES